Decoy Therapeutics Shareholders Approve Plan and Reverse Split

An announcement from Decoy Therapeutics ( (DCOY) ) is now available.

On February 24, 2026, Decoy Therapeutics Inc. held a virtual special meeting of stockholders at which a quorum of 2,696,758 common shares was present or represented by proxy. Stockholders voted on an equity incentive plan, a reverse stock split, and a proposal to allow adjournment of the meeting to seek additional proxies if needed.

Investors approved the 2026 Equity Incentive Plan, authorizing a new framework for stock-based compensation to employees and other eligible participants. They also backed a reverse stock split at a ratio between 1-for-4 and 1-for-15 at the board’s discretion, and approved an adjournment authorization that ultimately was not used because sufficient votes were obtained on the key proposals.

The most recent analyst rating on (DCOY) stock is a Sell with a $0.72 price target. To see the full list of analyst forecasts on Decoy Therapeutics stock, see the DCOY Stock Forecast page.

Spark’s Take on DCOY Stock

According to Spark, TipRanks’ AI Analyst, DCOY is a Neutral.

The score is driven primarily by weak financial performance (no revenue, ongoing losses, and negative free cash flow), partially offset by a low-debt balance sheet. Technicals are also a headwind with a longer-term downtrend and negative MACD, while valuation is constrained by continued losses and no dividend data.

To see Spark’s full report on DCOY stock, click here.

More about Decoy Therapeutics

Decoy Therapeutics Inc. operates in the biopharmaceutical sector, focusing on the development of therapeutic products. The company’s activities are funded and governed through publicly traded common stock, with corporate actions subject to approval by its stockholders.

Average Trading Volume: 2,301,379

Technical Sentiment Signal: Strong Sell

Current Market Cap: $4.52M

See more data about DCOY stock on TipRanks’ Stock Analysis page.